GP2b/3a Miscellaneous 1987-2001
Latest advances in anticoagulation therapy
CME credit.
Choose from a selection of simulated patient encounters to learn how to
recognize, diagnose, and manage patients who develop thrombocytopenia and
thrombosis associated with anticoagulation therapy.
http://www.medcases.com/gsk/gsk.asp
Guide to anticoagulant therapy: Heparin : a
statement for healthcare professionals from the American Heart Association
Hirsh J, et al.
Circulation 2001;103:2994-3018
http://www.circulationaha.org/cgi/content/full/103/24/2994
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=11413093
AVAILABLE FOR SELF-PACED LEARNING
ESC HIGHLIGHTS: OPTIMAL THROMBIN INHIBITION IN AMI
Release date: September 24, 2001
Drs Christopher P Cannon, Harvey White, and Jeffrey Popma discuss recent
highlights from the recent European Society of Cardiology meeting, including the
HERO-2 trial.
http://www.cybersessions.com
AHA 2000 Meeting Coverage
AHA 2000 Meeting News
The ESSENCE Study - Randomized trial of low molecular weight heparin (enoxaparin) versus unfractionated heparin for unstable coronary artery disease: one-year results. Efficacy and Safety of Subcutaneous Enoxaparin in Non-Q Wave Coronary Events
Goodman SG et al.
J Am Coll Cardiol 2000;36:693-8
http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?db=m&form=6&dopt=r&uid=0010987586
Click here to view the article synopsis at TCTMD
Adjunctive intracoronary dipyridamole in the interventional treatment of small coronary arteries: a prospectively randomized trial
Heidland UE || Strauer BE
Am Heart J 2000;139:1039-45
http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?db=m&form=6&dopt=r&uid=0010827385
In this randomized study on 491 PTCA of small coronary arteries with a diameter <2.75 mm, additional intracoronary application of dipyridamole was compared with conventional pretreatment consisting of heparin and
aspirin. Intracoronary dipyridamole was associated with a significant reduction of abrupt vessel closure (2.8% vs 8.6%; P =.005) and a nonsignificant reduction of myocardial infarction (1.6% vs 4.5%; P =.07).
Bivalirudin (Angiomax)
http://www.theheart.org/index.cfm?doc_id=20706
The recent FDA approval of the thrombin-specific anticoagulant bivalirudin
(Angiomax) may offer the alternative to heparin that interventionalists have been waiting
for. Heartbeat speaks with Dr A Michael Lincoff, interventional cardiologist and researcher at the Cleveland Clinic, about the place of this agent in clinical
practice.
Impact of new pharmacologic agents in the
treatment of acute thrombotic syndromes
Stone GW.
Am J Cardiol 1999;83:16E-20E.
http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?db=m&form=6&dopt=r&uid=10357577
Does platelet glycoprotein IIb/IIIa receptor
antibody improve in- hospital outcome of coronary stenting in high-risk thrombus
containing lesions?
Piamsomboon C, et al.
Catheter Cardiovasc Interv 1999;46:415-20.
http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?db=m&form=6&dopt=r&uid=10216005
Platelet glycoprotein IIb/IIIa antagonists
in percutaneous coronary revascularization
Dangas G, et al.
Am Heart J 1999;138:S16-23.
http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?db=m&form=6&dopt=r&uid=10385787
High dose bolus heparin as initial therapy
before primary angioplasty for acute myocardial infarction: results of the
Heparin in Early Patency (HEAP) pilot study
Verheugt FW, et al.
J Am Coll Cardiol 1998;31:289-93.
http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?db=m&form=6&dopt=r&uid=9462569
Stenting and IIb/IIIa Receptor Blockade in
Acute Myocardial Infarction: An Introduction to the CADILLAC Trial
Stone GW.
J Invasive Cardiol 1998;10 Suppl B:36B-47B.
http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?db=m&form=6&dopt=r&uid=10973337
An overview of the results of clinical
trials with glycoprotein IIb/IIIa inhibitors
Adgey AA.
Am Heart J 1998;135:S43-55.
http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?db=m&form=6&dopt=r&uid=9539495
Rationale for low-molecular weight heparin
in coronary stenting
Zidar JP.
Am Heart J 1997;134:S81-7.
http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?db=m&form=6&dopt=r&uid=9396639
Pharmacologic prevention of acute ischemic
complications of coronary angioplasty
Wheeldon N, et al.
Cathet Cardiovasc Diagn 1997;42:249-56.
http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?db=m&form=6&dopt=r&uid=9367094
Potential economic impact of glycoprotein
IIb-IIIa inhibitors in improving outcomes of patients with acute ischemic
coronary syndromes
McElwee NE, et al.
Am J Cardiol 1997;80:39B-43B.
http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?db=m&form=6&dopt=r&uid=9291245
Adjunctive infusion of antithrombin III
during percutaneous transluminal coronary angioplasty
Huber K, et al.
Eur Heart J 1997;18:362-3.
http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?db=m&form=6&dopt=r&uid=9076371
Inhibitors of platelet glycoprotein IIb/IIIa
receptors. Will they be useful when given chronically?
Willerson JT.
Circulation 1996;94:866-8.
http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?db=m&form=6&dopt=r&uid=8790016
Platelet membrane receptor glycoprotein IIb/IIIa
antagonism in unstable angina. The Canadian Lamifiban Study
Theroux P, et al.
Circulation 1996;94:899-905.
http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?db=m&form=6&dopt=r&uid=8790023
Glycoprotein IIb/IIIa receptor inhibitors:
putting the EPIC, IMPACT II, RESTORE, and EPILOG trials into perspective
Tcheng JE.
Am J Cardiol 1996;78:35-40.
http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?db=m&form=6&dopt=r&uid=8751845
Reduction of thrombotic and hemorrhagic
complications after stent implantation
Pan M, et al.
Am Heart J 1996;132:1119-26.
http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?db=m&form=6&dopt=r&uid=8969562
Prospective evaluation of hemostatic
predictors of subacute stent thrombosis after coronary Palmaz-Schatz stenting
Neumann FJ, et al.
J Am Coll Cardiol 1996;27:15-21.
http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?db=m&form=6&dopt=r&uid=8522689
Oral antiplatelet, antithrombotic efficacy
of DMP 728, a novel platelet GPIIb/IIIa antagonist
Mousa SA, et al.
Circulation 1996;93:537-43.
http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?db=m&form=6&dopt=r&uid=8565173
Platelet glycoprotein IIb/IIIa receptor
antagonists in coronary artery disease
Lefkovits J, et al.
Eur Heart J 1996;17:9-18.
http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?db=m&form=6&dopt=r&uid=8682137
Role of platelets in restenosis after
percutaneous coronary revascularization
Le Breton H, et al.
J Am Coll Cardiol 1996;28:1643-51.
http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?db=m&form=6&dopt=r&uid=8962547
EPILOG and CAPTURE trials halted because of
positive interim results
Ferguson JJ, 3rd.
Circulation 1996;93:637.
http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?db=m&form=6&dopt=r&uid=8640987
Platelet glycoprotein IIb/IIIa receptor
inhibitors in coronary artery disease
Cohen M.
Ann Intern Med 1996;124:843-4.
http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?db=m&form=6&dopt=r&uid=8610955
Management of intracoronary thrombosis
complicating percutaneous transluminal coronary angioplasty
Boston DR, et al.
Clin Cardiol 1996;19:536-42.
http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?db=m&form=6&dopt=r&uid=8818433
Clinical trials of Hirulog in patients
undergoing high-risk percutaneous transluminal coronary angioplasty
Bittl JA.
Coron Artery Dis 1996;7:449-54.
http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?db=m&form=6&dopt=r&uid=8889360
Antithrombotic potential of polymer-coated
stents eluting platelet glycoprotein IIb/IIIa receptor antibody
Aggarwal RK, et al.
Circulation 1996;94:3311-7.
http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?db=m&form=6&dopt=r&uid=8989145
Thrombolysis in the era of the randomized
trials
Zahger D, et al.
Curr Opin Cardiol 1995;10:372-80.
http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?db=m&form=6&dopt=r&uid=7549079
Novel antithrombotic approaches to coronary
artery disease
Topol EJ.
Am J Cardiol 1995;75:27B-33B.
http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?db=m&form=6&dopt=r&uid=7863968
Randomized double-blind comparison of two
doses of Hirulog with heparin as adjunctive therapy to streptokinase to promote
early patency of the infarct-related artery in acute myocardial infarction
Theroux P, et al.
Circulation 1995;91:2132-9.
http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?db=m&form=6&dopt=r&uid=7697841
Enhancing safety and outcomes with the newer
antithrombotic and antiplatelet agents
Tcheng JE.
Am Heart J 1995;130:673-9.
http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?db=m&form=6&dopt=r&uid=7668216
A comparison of hirudin with heparin in the
prevention of restenosis after coronary angioplasty. Helvetica Investigators
Serruys PW, et al.
N Engl J Med 1995;333:757-63.
http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?db=m&form=6&dopt=r&uid=7643882
Nonpeptide glycoprotein IIb/IIIa inhibitors.
5. Antithrombotic effects of MK-0383
Lynch JJ, Jr., et al.
J Pharmacol Exp Ther 1995;272:20-32.
http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?db=m&form=6&dopt=r&uid=7815334
Hirulog in the treatment of unstable angina.
Results of the Thrombin Inhibition in Myocardial Ischemia (TIMI) 7 trial
Fuchs J, et al.
Circulation 1995;92:727-33.
http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?db=m&form=6&dopt=r&uid=7641350
Novel antiplatelet therapies for treatment
of patients with ischemic heart disease: inhibitors of the platelet glycoprotein
IIb/IIIa integrin receptor
Frishman WH, et al.
Am Heart J 1995;130:877-92.
http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?db=m&form=6&dopt=r&uid=7572600
The role of platelets in arterial thrombosis
and the rationale for blockade of platelet GPIIb/IIIa receptors as
antithrombotic therapy
Coller BS.
Eur Heart J 1995;16 Suppl L:11-5.
http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?db=m&form=6&dopt=r&uid=8869013
Comparative safety profiles of hirulog and
heparin in patients undergoing coronary angioplasty. The Hirulog Angioplasty
Study Investigators
Bittl JA.
Am Heart J 1995;130:658-65.
http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?db=m&form=6&dopt=r&uid=7668214
Treatment with bivalirudin (Hirulog) as
compared with heparin during coronary angioplasty for unstable or postinfarction
angina. Hirulog Angioplasty Study Investigators
Bittl JA, et al.
N Engl J Med 1995;333:764-9.
http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?db=m&form=6&dopt=r&uid=7643883
Blockade of platelet membrane glycoprotein
Ib receptors delays intracoronary thrombogenesis, enhances thrombolysis, and
delays coronary artery reocclusion in dogs
Yao SK, et al.
Circulation 1994;89:2822-8.
http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?db=m&form=6&dopt=r&uid=8205697
Efficacy of adjunctive thrombolytic therapy
in percutaneous transluminal coronary angioplasty
Vaitkus PT, et al.
J Am Coll Cardiol 1994;24:1415-23.
http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?db=m&form=6&dopt=r&uid=7930268
Recombinant hirudin for unstable angina
pectoris. A multicenter, randomized angiographic trial
Topol EJ, et al.
Circulation 1994;89:1557-66.
http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?db=m&form=6&dopt=r&uid=8149521
Randomized trial of a GPIIb/IIIa platelet
receptor blocker in refractory unstable angina. European Cooperative Study Group
Simoons ML, et al.
Circulation 1994;89:596-603.
http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?db=m&form=6&dopt=r&uid=7508826
Adjunctive intracoronary infusion of
antithrombin III during percutaneous transluminal coronary angioplasty. Results
of a prospective, randomized trial
Schachinger V, et al.
Circulation 1994;90:2258-66.
http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?db=m&form=6&dopt=r&uid=7955182
Combination of platelet fibrinogen receptor
antagonist and direct thrombin inhibitor at low doses markedly improves
thrombolysis
Nicolini FA, et al.
Circulation 1994;89:1802-9.
http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?db=m&form=6&dopt=r&uid=8149546
Antiplatelet and antithrombotic efficacy of
DMP 728, a novel platelet GPIIb/IIIa receptor antagonist
Mousa SA, et al.
Circulation 1994;89:3-12.
http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?db=m&form=6&dopt=r&uid=8281661
Macrophage infiltration in acute coronary
syndromes. Implications for plaque rupture
Moreno PR, et al.
Circulation 1994;90:775-8.
http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?db=m&form=6&dopt=r&uid=8044947
Ancrod infusion for anticoagulation during
and after PTCA in a patient with heparin-induced thrombocytopenia
Moore JA, et al.
Cathet Cardiovasc Diagn 1994;32:286-7.
http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?db=m&form=6&dopt=r&uid=7954782
Inhibition of integrin function by a cyclic
RGD-containing peptide prevents neointima formation
Matsuno H, et al.
Circulation 1994;90:2203-6.
http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?db=m&form=6&dopt=r&uid=7955174
Thrombin generation in human coronary
arteries after percutaneous transluminal balloon angioplasty
Marmur JD, et al.
J Am Coll Cardiol 1994;24:1484-91.
http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?db=m&form=6&dopt=r&uid=7930280
A pilot, early angiographic patency study
using a direct thrombin inhibitor as adjunctive therapy to streptokinase in
acute myocardial infarction
Lidon RM, et al.
Circulation 1994;89:1567-72.
http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?db=m&form=6&dopt=r&uid=8149522
Oral verapamil inhibits platelet thrombus
formation in humans
L LL, et al.
Circulation 1994;89:630-4.
http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?db=m&form=6&dopt=r&uid=8313551
Cell adhesion molecules in coronary artery
disease
Jang Y, et al.
J Am Coll Cardiol 1994;24:1591-601.
http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?db=m&form=6&dopt=r&uid=7963103
Randomized prospective evaluation of
prolonged versus abbreviated intravenous heparin therapy after coronary
angioplasty
Friedman HZ, et al.
J Am Coll Cardiol 1994;24:1214-9.
http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?db=m&form=6&dopt=r&uid=7930242
Relation between procedural activated
coagulation time and outcome after percutaneous transluminal coronary
angioplasty
Ferguson JJ, et al.
J Am Coll Cardiol 1994;23:1061-5.
http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?db=m&form=6&dopt=r&uid=8144768
A pilot trial of recombinant
desulfatohirudin compared with heparin in conjunction with tissue-type
plasminogen activator and aspirin for acute myocardial infarction: results of
the Thrombolysis in Myocardial Infarction (TIMI) 5 trial
Cannon CP, et al.
J Am Coll Cardiol 1994;23:993-1003.
http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?db=m&form=6&dopt=r&uid=8144799
Effects of tissue plasminogen activator and
a comparison of early invasive and conservative strategies in unstable angina
and non-Q-wave myocardial infarction. Results of the TIMI IIIB Trial.
Thrombolysis in Myocardial Ischemia
Circulation 1994;89:1545-56.
http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?db=m&form=6&dopt=r&uid=8149520
Use of a monoclonal antibody directed
against the platelet glycoprotein IIb/IIIa receptor in high-risk coronary
angioplasty. The EPIC Investigation
N Engl J Med 1994;330:956-61.
http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?db=m&form=6&dopt=r&uid=8121459
Recombinant hirudin in patients with chronic,
stable coronary artery disease. Safety, half-life, and effect on coagulation
parameters
Zoldhelyi P, et al.
Circulation 1993;88:2015-22.
http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?db=m&form=6&dopt=r&uid=8222093
Thrombin inhibitors in unstable angina:
rebound or continuation of angina after argatroban withdrawal?
Willerson JT, et al.
J Am Coll Cardiol 1993;21:1048-51.
http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?db=m&form=6&dopt=r&uid=8459056
Safety and efficacy of recombinant hirudin (CGP
39 393) versus heparin in patients with stable angina undergoing coronary
angioplasty
van den Bos AA, et al.
Circulation 1993;88:2058-66.
http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?db=m&form=6&dopt=r&uid=8222099
Use of a direct antithrombin, hirulog, in
place of heparin during coronary angioplasty
Topol EJ, et al.
Circulation 1993;87:1622-9.
http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?db=m&form=6&dopt=r&uid=8491018
Usefulness and tolerability of hirulog, a
direct thrombin-inhibitor, in unstable angina pectoris
Sharma GV, et al.
Am J Cardiol 1993;72:1357-60.
http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?db=m&form=6&dopt=r&uid=8256726
Thrombin stimulates proliferation of
cultured rat aortic smooth muscle cells by a proteolytically activated receptor
McNamara CA, et al.
J Clin Invest 1993;91:94-8.
http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?db=m&form=6&dopt=r&uid=8380817
Lasting safe interruption of endarterectomy
thrombosis by transiently infused antithrombin peptide D-Phe-Pro-ArgCH2Cl in
baboons
Lumsden AB, et al.
Blood 1993;81:1762-70.
http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?db=m&form=6&dopt=r&uid=8461462
Initial experience with a direct
antithrombin, Hirulog, in unstable angina. Anticoagulant, antithrombotic, and
clinical effects
Lidon RM, et al.
Circulation 1993;88:1495-501.
http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?db=m&form=6&dopt=r&uid=8403297
SIN-1 reduces platelet adhesion and platelet
thrombus formation in a porcine model of balloon angioplasty
Groves PH, et al.
Circulation 1993;87:590-7.
http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?db=m&form=6&dopt=r&uid=8425303
Evidence for a rebound coagulation
phenomenon after cessation of a 4- hour infusion of a specific thrombin
inhibitor in patients with unstable angina pectoris
Gold HK, et al.
J Am Coll Cardiol 1993;21:1039-47.
http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?db=m&form=6&dopt=r&uid=8459055
Platelet activation during coronary
angioplasty in humans
Gasperetti CM, et al.
Circulation 1993;88:2728-34.
http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?db=m&form=6&dopt=r&uid=8252685
Is aggressive heparinization necessary for
elective PTCA?
Frierson JH, et al.
Cathet Cardiovasc Diagn 1993;28:279-82.
http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?db=m&form=6&dopt=r&uid=8462075
Anticoagulant effects of hirulog, a novel
thrombin inhibitor, in patients with coronary artery disease
Cannon CP, et al.
Am J Cardiol 1993;71:778-82.
http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?db=m&form=6&dopt=r&uid=8456753
Antithrombins: their potential as
antithrombotic agents
Weitz JI, et al.
Annu Rev Med 1992;43:9-16
http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?db=m&form=6&dopt=r&uid=1374601
Hirudins: antithrombin anticoagulants
Stringer KA, et al.
Ann Pharmacother 1992;26:1535-40.
http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?db=m&form=6&dopt=r&uid=1482812
PPACK-thrombin is a noncompetitive inhibitor
of alpha-thrombin binding to human platelets
Schmaier AH, et al.
Thromb Res 1992;67:479-89.
http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?db=m&form=6&dopt=r&uid=1448784
Clinical application of the synthetic
thrombin inhibitor, argatroban (MD-805)
Matsuo T, et al.
Semin Thromb Hemost 1992;18:155-60
http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?db=m&form=6&dopt=r&uid=1631564
Leeches to hirulogs and other
thrombin-directed antithrombotics
Fenton JW, 2nd.
Hematol Oncol Clin North Am 1992;6:1121-9.
http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?db=m&form=6&dopt=r&uid=1400076
Heparin and the thrombin inhibitor
argatroban enhance fibrinolysis by infused or bolus-injected saruplase (r-scu-PA)
in rabbit femoral artery thrombosis
Schneider J.
Thromb Res 1991;64:677-89.
http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?db=m&form=6&dopt=r&uid=1798957
Integrins
Ruoslahti E.
J Clin Invest 1991;87:1-5.
http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?db=m&form=6&dopt=r&uid=1985087
Developing relationships: arterial platelet
adhesion, glycoprotein Ib, and leucine-rich glycoproteins
Roth GJ.
Blood 1991;77:5-19.
http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?db=m&form=6&dopt=r&uid=1984803
Hirudin and derivatives as anticoagulant
agents
Markwardt F.
Thromb Haemost 1991;66:141-52.
http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?db=m&form=6&dopt=r&uid=1926044
Role of thrombin in arterial thrombosis:
implications for therapy
Chesebro JH, et al.
Thromb Haemost 1991;66:1-5.
http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?db=m&form=6&dopt=r&uid=1926039
Importance of antithrombin therapy during
coronary angioplasty
Chesebro JH, et al.
J Am Coll Cardiol 1991;17:96B-100B.
http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?db=m&form=6&dopt=r&uid=1849931
Comparative effects of aspirin, a synthetic
thrombin inhibitor and a monoclonal antiplatelet glycoprotein IIb/IIIa antibody
on coronary artery reperfusion, reocclusion and bleeding with recombinant
tissue- type plasminogen activator in a canine preparation
Yasuda T, et al.
J Am Coll Cardiol 1990;16:714-22.
http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?db=m&form=6&dopt=r&uid=2117620
Lysis of plasminogen activator-resistant
platelet-rich coronary artery thrombus with combined bolus injection of
recombinant tissue-type plasminogen activator and antiplatelet GPIIb/IIIa
antibody
Yasuda T, et al.
J Am Coll Cardiol 1990;16:1728-35.
http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?db=m&form=6&dopt=r&uid=2123910
Acceleration of recombinant tissue-type
plasminogen activator-induced thrombolysis and prevention of reocclusion by the
combination of heparin and the Arg-Gly-Asp-containing peptide bitistatin in a
canine model of coronary thrombosis
Shebuski RJ, et al.
Circulation 1990;82:169-77.
http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?db=m&form=6&dopt=r&uid=2114233
Role of thrombolysis and thrombin in
patients with acute coronary occlusion during percutaneous transluminal coronary
angioplasty
Gulba DC, et al.
J Am Coll Cardiol 1990;16:563-8.
http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?db=m&form=6&dopt=r&uid=2117619
Pharmacodynamic study of F(ab')2 fragments
of murine monoclonal antibody 7E3 directed against human platelet glycoprotein
IIb/IIIa in patients with unstable angina pectoris
Gold HK, et al.
J Clin Invest 1990;86:651-9.
http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?db=m&form=6&dopt=r&uid=2384607
Demonstration of Ac-Arg-Gly-Asp-Ser-NH2 as
an antiaggregatory agent in the dog by intracoronary administration
Shebuski RJ, et al.
Thromb Haemost 1989;61:183-8.
http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?db=m&form=6&dopt=r&uid=2749593
Receptor-specific antiplatelet therapy
Ruggeri ZM.
Circulation 1989;80:1920-2.
http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?db=m&form=6&dopt=r&uid=2598449
Prevention of reoccluding platelet-rich
thrombi in canine femoral arteries with a novel peptide antagonist of platelet
glycoprotein IIb/IIIa receptors
Haskel EJ, et al.
Circulation 1989;80:1775-82.
http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?db=m&form=6&dopt=r&uid=2513145
Thrombin is an important mediator of
platelet aggregation in stenosed canine coronary arteries with endothelial
injury
Eidt JF, et al.
J Clin Invest 1989;84:18-27.
http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?db=m&form=6&dopt=r&uid=2661588
Abolition of in vivo platelet thrombus
formation in primates with monoclonal antibodies to the platelet GPIIb/IIIa
receptor. Correlation with bleeding time, platelet aggregation, and blockade of
GPIIb/IIIa receptors
Coller BS, et al.
Circulation 1989;80:1766-74.
http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?db=m&form=6&dopt=r&uid=2598436
Monoclonal antibody against the platelet
glycoprotein (GP) IIb/IIIa receptor prevents coronary artery reocclusion after
reperfusion with recombinant tissue-type plasminogen activator in dogs
Yasuda T, et al.
J Clin Invest 1988;81:1284-91.
http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?db=m&form=6&dopt=r&uid=2832448
The platelet membrane glycoprotein IIb-IIIa
complex
Phillips DR, et al.
Blood 1988;71:831-43.
http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?db=m&form=6&dopt=r&uid=2833328
Effects of monoclonal antibodies against the
platelet glycoprotein IIb/IIIa complex on thrombosis and hemostasis in the
baboon
Hanson SR, et al.
J Clin Invest 1988;81:149-58.
http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?db=m&form=6&dopt=r&uid=2961790
Interruption of acute platelet-dependent
thrombosis by the synthetic antithrombin D-phenylalanyl-L-prolyl-L-arginyl
chloromethyl ketone
Hanson SR, et al.
Proc Natl Acad Sci U S A 1988;85:3184-8.
http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?db=m&form=6&dopt=r&uid=3362867
Rapid and sustained coronary artery
recanalization with combined bolus injection of recombinant tissue-type
plasminogen activator and monoclonal antiplatelet GPIIb/IIIa antibody in a
canine preparation
Gold HK, et al.
Circulation 1988;77:670-7.
http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?db=m&form=6&dopt=r&uid=3124974
Inhibition of human platelet function in
vivo with a monoclonal antibody. With observations on the newly dead as
experimental subjects
Coller BS, et al.
Ann Intern Med 1988;109:635-8.
http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?db=m&form=6&dopt=r&uid=3421576
New perspectives in cell adhesion: RGD and
integrins
Ruoslahti E, et al.
Science 1987;238:491-7.
http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?db=m&form=6&dopt=r&uid=2821619